NCT02419495: Phase IB of Selinexor in Combination With Standard Chemotherapy in Patients With Advanced Malignancies

NCT02419495
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor, Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Primary CNS tumor or CNS tumor involvement- see trial for details
https://ClinicalTrials.gov/show/NCT02419495

Comments are closed.

Up ↑